Sayed Elshaimaa G, Hussein Amal K, Khaled Khaled A, Ahmed Osama A A
Department of Pharmaceutical Technology, Faculty of Pharmacy, Minia University, Minia, Egypt.
Department of Pharmaceutical Technology, Faculty of Pharmacy, Minia University, Minia, Egypt ; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Drug Des Devel Ther. 2015 Mar 10;9:1427-35. doi: 10.2147/DDDT.S80697. eCollection 2015.
The aim of the study was to improve corneal penetration and bioavailability of ofloxacin (OFX) eye preparations. OFX was incorporated in poly (lactide-co-glycolide) as biodegradable microspheres using oil in oil emulsion solvent evaporation technique. The prepared OFX microspheres were then incorporated in Gelrite(®) in situ gel preparation. In addition, OFX Gelrite-based in situ gel formulations were prepared. OFX formulations were characterized for gelling capacity, viscosity, and rheological properties. Release studies for OFX microspheres, OFX in situ gel, and OFX-loaded microspheres in situ gel formulations were carried out to investigate release characteristics of the drug. The prepared OFX formulations were then investigated in vivo compared with commercially available OFX eyedrops. Results showed that the optimum Gelrite concentration was at 0.4%-0.7% w/v; the prepared formulations were viscous liquid transformed into a pourable gel immediately after the addition of simulated tear fluid with a gelling factor of 27-35. Incorporation of OFX-loaded microspheres in Gelrite solution (0.4% w/v) significantly altered the release profiles of OFX-loaded microspheres in situ gel formula compared with the corresponding OFX gels and OFX microspheres. In vivo results in rabbits showed that OFX-loaded microspheres in situ gel formula improved the relative bioavailability by 11.7-fold compared with the commercially available OFX eyedrops. In addition, the longer duration of action of OFX-loaded microspheres in situ gel formula preparations is thought to avoid frequent instillations, which improves patient tolerability and compliance.
本研究的目的是提高氧氟沙星(OFX)眼部制剂的角膜渗透性和生物利用度。采用油包油乳液溶剂蒸发技术,将OFX包裹于聚(丙交酯-乙交酯)中制成可生物降解的微球。然后将制备好的OFX微球加入到Gelrite(®)原位凝胶制剂中。此外,还制备了基于Gelrite的OFX原位凝胶制剂。对OFX制剂的胶凝能力、粘度和流变学性质进行了表征。开展了OFX微球、OFX原位凝胶以及载有OFX的微球原位凝胶制剂的释放研究,以考察药物的释放特性。然后将制备好的OFX制剂与市售OFX滴眼液进行体内比较研究。结果表明,Gelrite的最佳浓度为0.4%-0.7% w/v;所制备的制剂为粘性液体,加入模拟泪液后立即转变为可倾倒的凝胶,胶凝因子为27-35。与相应的OFX凝胶和OFX微球相比,将载有OFX的微球加入到Gelrite溶液(0.4% w/v)中显著改变了载有OFX的微球原位凝胶制剂的释放曲线。家兔体内实验结果表明,与市售OFX滴眼液相比,载有OFX的微球原位凝胶制剂的相对生物利用度提高了11.7倍。此外,载有OFX的微球原位凝胶制剂作用时间更长,被认为可避免频繁滴注,从而提高患者的耐受性和依从性。